(2S,4S)-methanesulfonic acid 2-tert-butoxycarbonylamino-5-methanesulfonyloxy-4-methyl-pentyl ester | 951313-20-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: (2S,4S)-methanesulfonic acid 2-tert-butoxycarbonylamino-5-methanesulfonyloxy-4-methyl-pentyl ester
• 英文别名: methanesulfonic acid 2(S)-tert-butoxycarbonylamino-5-methanesulfonyloxy-4(S)-methylpentyl ester；(2S,4S)-2-((tert-butoxycarbonyl)amino)-4-methylpentane-1,5-diyl dimethanesulfonate；[(2S,4S)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-methylsulfonyloxypentyl] methanesulfonate
• CAS: 951313-20-5
• 化学式: C₁₃H₂₇NO₈S₂
• 分子量: 389.491
• InChiKey: NQPSKPGQESKQCB-QWRGUYRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  24
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  142
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2S,4S)-methanesulfonic acid 2-tert-butoxycarbonylamino-5-methanesulfonyloxy-4-methyl-pentyl ester 生成 tert-butyl N-(1-benzyl-5-methylpiperidin-3-yl)carbamate
  参考文献：
  名称：

  Coupling process for preparing quinolone intermediates

  摘要：

  制备7-环氨基-1-环丙基-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸的过程。适用于此过程的硼酸酯化合物。

  公开号：

  US07456279B2
• 作为产物：
  描述：

  甲基磺酰氯 在 三乙胺 、 碳酸氢钠 作用下， 以 醋酸异丙酯 、 水 为溶剂， 生成 (2S,4S)-methanesulfonic acid 2-tert-butoxycarbonylamino-5-methanesulfonyloxy-4-methyl-pentyl ester
  参考文献：
  名称：

  Hydride reduction process for preparing quinolone intermediates

  摘要：

  从环状中间体制备无环二醇中间体的氢化过程，在抗菌喹诺酮合成中很有用。

  公开号：

  US20070232806A1

文献信息

• Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
  申请人：Redman-Furey Nancy Lee

  公开号：US20070232650A1

  公开（公告）日：2007-10-04

  The present invention is directed to malate salts of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid, and its polymorphs. The present invention is also directed to pharmaceutical compositions comprising the described salts and polymorphs.

  本发明涉及（3S,5S）-7-[3-氨基-5-甲基哌啶基]-1-环丙基-1,4-二氢-8-甲氧基-4-氧基-3-喹啉羧酸的苹果酸盐及其多晶形式。本发明还涉及包含所述盐和多晶形式的药物组合物。
• [EN] BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS PYRIDAZINES BICYCLIQUES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2012148775A1

  公开（公告）日：2012-11-01

  The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式I和I'的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文披露的化合物的药物组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症中的应用。
• Coupling Process For Preparing Quinolone Intermediates
  申请人：Reilly Michael

  公开号：US20090111991A1

  公开（公告）日：2009-04-30

  Process for making 7-cycloamino-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids. Borate ester compounds suitable for use in such process.

  制备7-环氨基-1-环丙基-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸的过程。适用于该过程的硼酸酯化合物。
• Bicyclic Pyridazine Compounds as PIM Inhibitors
  申请人：D'amico Derin C.

  公开号：US20140221344A1

  公开（公告）日：2014-08-07

  The invention relates to bicyclic compounds of formulas I and I′, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及式I和I'的双环化合物及其盐。在某些实施例中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含所述化合物的制药组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症方面的应用。
• ANTIMICROBIAL PARENTERAL FORMULATION
  申请人：Lee Lih-Huei

  公开号：US20090042932A1

  公开（公告）日：2009-02-12

  This invention relates to a parenteral formulation containing an effective amount of the compound of the following formula I: water, and an isotonic agent. Also disclosed is a method of treating an infectious disease by administering this formula to a subject via parenteral injection or infusion.

  本发明涉及一种含有以下化学式I化合物的静脉注射配方，其中还包括水和等渗剂的有效量。同时还揭示了一种通过静脉注射或输注将该配方用于治疗传染病的方法。